Dave's Repurchase of FTX Convertible Note for $71 Million Finalized

Stock Information for G1 Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About G1 Therapeutics Inc.

Dave Reports Record Fourth Quarter and Full Year 2023 Results; Reaches Significant Quarterly Profitability Milestone
Dave to Participate at the Wolfe Fintech Forum on March 14
Neobank Dave Joins the American Fintech Council to Create Financial Inclusivity in Digital Banking
Aisera & Dave Launch DaveGPT, a Generative AI Customer Service Assistant to Enable Personalized On-Demand Support
Dave Announces Repurchase of $100 million Convertible Note from FTX for $71 million
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Dave Inc. (NASDAQ: DAVE) and Encourages Investors to Contact the Firm
Dave Announces Third Quarter 2023 Results
Dave to Report Third Quarter 2023 Results on November 7, 2023 at 4:30 p.m. ET

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.